Merck in the NEWS
Merck (MRK) announced that the U.S. FDA has accepted for review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of HER2 negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
The American Agency's acceptance of . . .
This content is for paid subscribers.
Today’s Highlights
April 14, 2023
 for The Treatment of HER2 Negative Gastric Adenocarcinoma){kind=link}